Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.
Guillaume Marquis-GravelAmanda StebbinsLisa M WruckMatthew T RoeMark B EffronBradley G HammillJeffrey WhittleJeffrey J VanWormerHolly R RobertsonJacqueline D AlikhaaniSunil KripalaniPeter M FarrehiSaket GirotraCatherine P BenzigerTamar S PolonskyJ Greg MerrittKamal GuptaThomas E McCormickKirk U KnowltonSandeep K JainAjar KocharRussell L RothmanRobert A HarringtonAdrian F HernandezW Schuyler JonesPublished in: Journal of the American Heart Association (2024)
Age does not modify the impact of aspirin dosing (81 mg or 325 mg daily) on clinical end points in secondary prevention of atherosclerotic cardiovascular disease.